IGF-I attenuates diabetes-induced cardiac contractile dysfunction in ventricular myocytes. - Wikidata - awgldk - TriplyDB

IGF-I attenuates diabetes-induced cardiac contractile dysfunction in ventricular myocytes.

IGF-I attenuates diabetes-induced cardiac contractile dysfunction in ventricular myocytes.

http://www.wikidata.org/entity/Q44129300

about

Insulin-like growth factor-1 protects ischemic murine myocardium from ischemia/reperfusion associated injury Diabetes and cardiovascular disease: Epidemiology, biological mechanisms, treatment recommendations and future research Insulin-like growth factor-1 deficiency and metabolic syndrome Adverse perinatal environment contributes to altered cardiac development and function.Azelnidipine prevents cardiac dysfunction in streptozotocin-diabetic rats by reducing intracellular calcium accumulation, oxidative stress and apoptosis.Changes in insulin-like growth factor-I and its binding proteins are associated with diabetes mellitus in older adults.Insulin-like growth factor 1 alleviates high-fat diet-induced myocardial contractile dysfunction: role of insulin signaling and mitochondrial function.Analysis of the Zucker Diabetic Fatty (ZDF) type 2 diabetic rat model suggests a neurotrophic role for insulin/IGF-I in diabetic autonomic neuropathy.Oxidative stress and stress signaling: menace of diabetic cardiomyopathy.Cardiovascular remodeling in response to long-term exposure to fine particulate matter air pollution Altered calcium homeostasis does not explain the contractile deficit of diabetic cardiomyopathy.Trace elements in diabetic cardiomyopathy: An electrophysiological overview Protection of the heart by treatment with a divalent-copper-selective chelator reveals a novel mechanism underlying cardiomyopathy in diabetic rats.UCF-101 mitigates streptozotocin-induced cardiomyocyte dysfunction: role of AMPK.Cardiac health in women with metabolic syndrome: clinical aspects and pathophysiology.Insulin-like growth factor-1 improves diabetic cardiomyopathy through antioxidative and anti-inflammatory processes along with modulation of Akt/GSK-3β signaling in rats A new insight of mechanisms, diagnosis and treatment of diabetic cardiomyopathy.Impairment of calcium ATPases by high glucose and potential pharmacological protection.Mechanisms underlying the impaired contractility of diabetic cardiomyopathy.The regulation of sarco(endo)plasmic reticulum calcium-ATPases (SERCA).Hormones and the heart: Does the cardiovascular system need growth hormone in adult life?Impact of insulin-like growth factor-I on migration, proliferation and Akt-ERK signaling in early and late-passages of vascular smooth muscle cells.Inhibition of phospholamban phosphorylation by O-GlcNAcylation: implications for diabetic cardiomyopathy.Effects of insulin replacement on cardiac apoptotic and survival pathways in streptozotocin-induced diabetic rats.Tempol ameliorates cardiac fibrosis in streptozotocin-induced diabetic rats: role of oxidative stress in diabetic cardiomyopathy.Modulating the functional performance of bioengineered heart muscle using growth factor stimulation.Dimethylthiourea normalizes velocity-dependent, but not force-dependent, index of ventricular performance in diabetic rats: role of myosin heavy chain isozyme.IGF-I alleviates diabetes-induced RhoA activation, eNOS uncoupling, and myocardial dysfunction.Characterization of alterations in diabetic myocardial tissue using high resolution MRI.Temporal changes in cardiac force- and flow-generation capacity, loading conditions, and mechanical efficiency in streptozotocin-induced diabetic rats.Sex difference in cardiomyocyte function in normal and metallothionein transgenic mice: the effect of diabetes mellitus.Impaired Left Atrial Conduit Function in Coronary Artery Disease Patients With Poorly Controlled Diabetes: Two-Dimensional Speckle-Tracking Echocardiographic Study.Calcium Signaling in the Ventricular Myocardium of the Goto-Kakizaki Type 2 Diabetic Rat.

P2860

Q24802256-7EC777BF-8D78-444C-8452-8DF5B0355CD1 Q26782844-C76BB1DE-68A7-4C09-8CCA-AFB7C329C429 Q28072410-23509607-7C60-43A0-8EB3-93EB008FE5F5 Q33568838-D9702B35-A6DB-4FC0-BA8D-428B2AA7AB6C Q35602720-E8057E61-E571-454E-BEB8-86F69A1B8DE0 Q35626194-0432AF31-2424-447B-85E7-5FF80C95F4EA Q35783723-85EE7C16-807B-4CCC-8CA4-E2B8E4A768FB Q35791559-799A7DF6-874A-48B2-83BB-3DFA4CB8D304 Q36204491-9CBA7DD4-6EEE-4366-9870-49716E2FDDD2 Q36742956-B0774AD8-82D6-4C3D-8EFD-733A54B2C6BA Q36807692-846E8679-A576-4D45-B6F2-89C55AFECA07 Q37101642-4E81AEEC-39C5-46A7-A26E-3F92A5B3DDC6 Q37360093-95A87CC7-B372-4D94-8E8A-8C230B6B47B7 Q37391764-030D522C-83DA-4FDD-94AE-E936DF0DC15F Q37391968-B95C7BF1-9888-4E6D-B7D7-7109F5FF328E Q37409973-BF77F131-8579-4585-A1D0-25345727C318 Q37983012-47CAE946-6F54-40B7-8F0B-6469CF82630C Q38109649-FA76C37B-7274-4774-933A-1FA435CD960D Q38234562-B60ADA8A-BACC-46A9-8EEC-39D05441F6D8 Q38366647-6DC13735-3FA3-4A92-871A-D461E591BEA2 Q41108140-36D9F732-CD4F-420B-BFF3-10F1FC54206B Q42520760-5781A7DF-C51E-4E2F-83BF-6912F6B1431E Q43059618-14736543-51B0-4F26-8DB9-056C772F89EE Q43283427-4C8387DC-368A-40FA-98F4-793B8F9A491B Q43915235-E26E4B37-7740-472C-ABA1-809961DD7A6F Q44289471-349CD8D6-98C7-465E-ACA9-3D20C039256E Q45919528-3B67B19B-71DA-4BF2-800C-4B3B2BFF4298 Q46805078-2944FB44-1C27-4459-98B9-3BA7412C7A3F Q46856995-4202A164-A0BB-4AB8-992F-E1A5F653AEE0 Q46869141-AAFAACDE-0F91-438B-BE3B-A0B6F2403F65 Q46892926-732D1A23-F8C2-49DC-B10F-AB0D6038A609 Q48585297-50262157-874D-42AA-B163-E1BC709B6E76 Q55049902-BA53C93B-E8EE-484E-A5DE-00D9982B45FF

P2860

IGF-I attenuates diabetes-induced cardiac contractile dysfunction in ventricular myocytes.

http://www.wikidata.org/entity/Q44129300

description

2002 nî lūn-bûn

@nan

2002年の論文

@ja

2002年学术文章

@wuu

2002年学术文章

@zh

2002年学术文章

@zh-cn

2002年学术文章

@zh-hans

2002年学术文章

@zh-my

2002年学术文章

@zh-sg

2002年學術文章

@yue

2002年學術文章

@zh-hant

name

IGF-I attenuates diabetes-indu ...... ction in ventricular myocytes.

@en

IGF-I attenuates diabetes-indu ...... ction in ventricular myocytes.

@nl

type

label

IGF-I attenuates diabetes-indu ...... ction in ventricular myocytes.

@en

IGF-I attenuates diabetes-indu ...... ction in ventricular myocytes.

@nl

prefLabel

IGF-I attenuates diabetes-indu ...... ction in ventricular myocytes.

@en

IGF-I attenuates diabetes-indu ...... ction in ventricular myocytes.

@nl

P1433

Q44129300-9D325D12-F1A9-44E5-A3ED-522049CF5821

P1476

Q44129300-98EA9E58-E779-40B7-89BD-D98A807BDD52

P2093

Q44129300-010D7E4B-4693-4EA9-B4AB-E7AE811B47B6

Q44129300-23CA22A3-2368-4E64-AE7C-E9409123A746

Q44129300-467A2DAA-88EB-4F2D-9848-56916DDB0339

Q44129300-8C034610-55D4-49E9-B837-0FEB7E2916EC

Q44129300-9EAD42C4-BC90-4A5C-B087-8B8387B923F5

P2860

Q44129300-0D0D7BED-3C8D-4F86-ACAE-B451E8B3AE42

Q44129300-0D957D44-154A-4648-9ED0-1AE02F1510A7

Q44129300-0FC3AEBB-80BF-4970-B539-EC96F0209F76

Q44129300-145238A7-0D29-42D0-85E3-BCB1C36A87FB

Q44129300-1775AE82-F745-4189-9252-4E40F50F93CD

Q44129300-1CEEEF8B-3BEC-47C4-B42A-B5BF0ACC44C9

Q44129300-23FA7A48-7D14-4794-988D-2F7CF3A23965

Q44129300-24A6B15B-A040-4B5A-9AA0-52107F12201A

Q44129300-2C1FEFC8-FA8A-425F-95C3-BC7BC4751365

Q44129300-3A3F4073-4655-4C02-A6A4-E2C8AA5B1A91

P304

Q44129300-6020831E-D8D1-4E78-BB4F-F9CC159241D6

P31

Q44129300-3962BC63-BC1B-4B14-A87A-0A0E845196DB

P356

Q44129300-6C4BF0F8-91AC-4186-BAE9-6D249CFF20F8

P433

Q44129300-CC4AC1E4-40FE-4AD8-9600-98FD2C31275E

P478

Q44129300-7D86E6B2-A83D-410D-8C7C-93CF48C33823

P577

Q44129300-082E0A14-6BD1-4EE7-BCB0-5FEDBA19DA94

P5875

Q44129300-4755EDB5-01CC-4891-BFE4-D834FE518E08

P698

Q44129300-DE134F29-06D5-4427-A475-E311EF71D6FF

P356

AJPENDO.00003.2002

P1433

American Journal of Physiology - Endocrinology and Metabolism

P1476

IGF-I attenuates diabetes-indu ...... ction in ventricular myocytes.

@en

P2093

Faye L Norby

http://www.w3.org/2001/XMLSchema#string

Jinhong Duan

http://www.w3.org/2001/XMLSchema#string

Jun Ren

http://www.w3.org/2001/XMLSchema#string

Kadon K Hintz

http://www.w3.org/2001/XMLSchema#string

Loren E Wold

http://www.w3.org/2001/XMLSchema#string

P2860

Cardiac excitation-contraction coupling

Alterations in the growth hormone-insulin-like growth factor axis in insulin dependent diabetes mellitus.

Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association.

Insulin-like growth factor I as a cardiac hormone: physiological and pathophysiological implications in heart disease.

Insulin-like growth factor-I and diabetes. A review.

Comparison of the metabolic effects of recombinant human insulin-like growth factor-I and insulin. Dose-response relationships in healthy young and middle-aged adults.

Effects of insulin-like growth factor-I on glucose tolerance, insulin levels, and insulin secretion.

Regulation of binding proteins for insulin-like growth factors (IGF) in humans. Increased expression of IGF binding protein 2 during IGF I treatment of healthy adults and in patients with extrapancreatic tumor hypoglycemia.

Insulin signaling coordinately regulates cardiac size, metabolism, and contractile protein isoform expression

Effect of insulin-like growth factor-1 on the responses to and recognition of hypoglycemia in humans. A comparison with insulin.

P304

E658-66

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1152/AJPENDO.00003.2002

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

283

http://www.w3.org/2001/XMLSchema#string

P577

2002-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

11171156

http://www.w3.org/2001/XMLSchema#string

P698

12217882

http://www.w3.org/2001/XMLSchema#string